



March 24, 2020

Supporting a study to evaluate the efficacy and safety of Pirfenidone  
for the novel Coronavirus infection 2

GNI Group Ltd. is pleased to report that our consolidated subsidiary Beijing Continent Pharmaceutical Co., Ltd is supporting the First Affiliated Hospital of Guangzhou Medical University for its clinical study to evaluate the efficacy and safety of Pirfenidone for the novel Coronavirus infection.